Eutilex Co Ltd
263050
Company Profile
Business description
Eutilex Co Ltd is a Korean that operates in the anti-tumor immunotherapy market. The company develops anti-tumor T cell therapy and antibody therapeutics based on its immunotherapy technology. Its pipeline products include T Cell Therapy (4-1BB CTL), CAR-T, and Antibody.
Contact
Daeryung Technotown 17
Suite 1401
Gasan Digital 1-ro 25
Geumcheon-gu
Seoul08594
KORT: +82 234027310
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
125
Stocks News & Analysis
stocks
Insignia Financial: Revised deal still attractive
The offer price is well above our fair value.
stocks
Going into earnings, is Alphabet stock a buy, a sell, or fairly valued?
With the monetization of GenAI, here’s what we think of Alphabet’s stock
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,001.40 | 59.90 | 0.67% |
| CAC 40 | 7,837.23 | 92.82 | 1.20% |
| DAX 40 | 24,168.95 | 127.05 | 0.53% |
| Dow JONES (US) | 44,647.69 | 145.25 | 0.33% |
| FTSE 100 | 9,066.81 | 43.00 | 0.48% |
| HKSE | 25,538.07 | 408.04 | 1.62% |
| NASDAQ | 20,903.26 | 10.57 | 0.05% |
| Nikkei 225 | 41,171.32 | 1,396.40 | 3.51% |
| NZX 50 Index | 12,794.06 | 39.68 | -0.31% |
| S&P 500 | 6,323.70 | 14.08 | 0.22% |
| S&P/ASX 200 | 8,737.20 | 60.00 | 0.69% |
| SSE Composite Index | 3,582.30 | 0.44 | 0.01% |